Long QT syndrome (LQTS) is a heart disease characterized by delayed repolarization which can result in sudden cardiac death. Family-based linkage studies have explained the genetic causes of 75-80% of LQTS cases leaving ~20% of LQTS cases elusive. It is statistically infeasible to use traditional genome-wide association studies to discover these remaining genetic causes; therefore alternative approaches are required. To discover patient-specific differential eQTL (deQTL), we will use the human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) model to compare gene expression in hiPSC-CMs from 50 patients with LQTS harboring known LQTS variants (Phenotype+, Genotype+), 50 patients with LQTS and not harboring any known LQTS variant (P+G-), and 50 controls known not to have LQTS (P-G-). For each patient's hiPSC-CMs, we will electrophysiologically phenotype the cells for prolonged action potential. To establish deQTL, we will then compare differential gene/splice variant isoforms expression and correlate these with LQTS disease status and in vitro phenotype. This will allow us to identify transcriptional patterns uniquely present in P+G- but not in neither controls nor P+G+. Having QT intervals measured clinically and in patient-derived cardiomyocytes will allow us to pinpoint altered gene expression associated with prolonged action potential in LQTS patients. We will first focus on whole-genome sequencing-identified variants associated with P+G+ specific genes when compared to P-G-, completing a genotype-phenotype association analysis to pinpoint deQTL that are over-represented in LQTS patients. We will then complete a comparison of P+G+ vs. P+G- and P+G- vs. P-G- to identify deQTL unique to patients who do not have known LQTS variants. By identifying SNPs that are causative in regulating gene expression in LQTS, we will be able to find highly powered genetic modifiers of the LQTS phenotype and then validate them by genome editing in the hiPSC-CM model. Finally, we will genotype family members for identified modifiers to detect candidate modifiers implicated in LQTS variable expressivity. Then we will sequentially correct candidate modifiers in patient-specific hiPSCs and phenotype cellular electrophysiology. This will allow us to quantify the contribution of these modifiers in LQTS incomplete penetrance and variable expressivity.
|Effective start/end date||7/1/21 → 6/30/24|
- American Heart Association (AHA Award Number: 852609)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.